Community/Retail

Ulipristal is a progesterone receptor modulator that prevents pregnancy by blocking the release of an egg from the ovary and inhibiting implantation in the uterus.

The time is right for PBM reform, but the American people might be better served if Congress goes back to the drawing board for a different approach.

Efruxifermin is undergoing 3 phase 3 clinical trials to evaluate its safety, efficacy, and tolerability in metabolic dysfunction-associated steatohepatitis (MASH).

Investigators noted that the differences between the 3 respiratory infections were not as pronounced during the 2023-2024 season.

Investigators found that 60% of individuals with type 2 diabetes are vitamin D deficient.

Prescription stimulant dispensing was greatly impacted by the COVID-19 pandemic and drug shortages.

The results highlight hemoglobin A1c/high-density lipoprotein cholesterol as a potential clinical marker for long-term stroke risk.

For pharmacists wondering whether bismuth quadruple therapy still reigns as the gold standard, the wait is over—the latest recommendations are here.

Overall, there is no long-term increased risk of developing thyroid cancer after initiating treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist, although there is a short-term increase.

Angiotensin receptor neprilysin inhibitors show promise as an alternative to standard management of resistant hypertension.

The approval marks the first subcutaneous infusion device approved for the treatment of Parkinson disease, providing a new option for patients with serious disease who are unresponsive to other therapies.

World Cancer Day, observed annually on February 4th, is a global initiative aimed at raising awareness, reducing stigma, and promoting equitable access to cancer care, with pharmacy professionals playing a vital role in prevention, treatment, and support for patients and communities.

Rising seasonal viruses and emerging concerns emphasize the need for public awareness and prevention.

Antiviral treatments can accelerate healing and reduce complications.

Three experts from UPMC Health Plan highlight the importance of treating patients’ physical, mental, and social health when managing diabetes, rather than the disease alone.

The phase 1b/2a results show the potential of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist.

Health care professionals, particularly pharmacists, can recommend that patients take over-the-counter supplements, such as melatonin, to facilitate REM sleep.

Many patients do not attain sufficient disease control with inhaled corticosteroids in combination with long-acting β-2 agonists and remain vulnerable to exacerbations.

S-337395 demonstrated an 88.4% reduction in viral load and had a statistically significant improvement in clinical symptoms scores.

Although there were increases in prescriptions during the studies’ durations, the proportion of anxiety or pain medications on the same day of intrauterine device (IUD) insertion procedures were low.

Statin use is not associated with a change in incident chronic kidney disease (CKD) and estimated glomerular filtration rate in adult patients aged 65 and older.

The diabetes treatment landscape is rapidly evolving, with new combination therapies and oral GLP-1 medications, positioning pharmacists to have an important role in personalizing care.

The approval includes indications for rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and COVID-19.

Atopic dermatitis significantly impacts quality of life, and requires personalized management through trigger identification, skin barrier maintenance, and a range of topical, oral, and biologic therapies to reduce symptoms and prevent flare-ups.

The drug is a selective NaV1.8 pain signal inhibitor and is the first new class of medication to treat acute pain in over 20 years.

Additionally, the authors observe that childhood-onset epilepsy is associated with an earlier age at the onset of amyloidosis.

The court also addressed the employer’s basis for ordering a drug test.

This marks the first US biologic license application filing acceptance for a biosimilar candidate to golimumab.

This follows the approval of everolimus tablets for patients aged 1 and older in January 2025.

Through similar targeting of the RdRp enzyme, these treatments could offer groundbreaking new options for patients with COVID-19 if proven effective in real-world trials.